Brought to you by 
MPM leads $12mm Series E round for Elixir Pharmaceuticals
22 Mar 2012
Executive Summary
Elixir Pharmaceuticals (metabolic diseases) has raised $12mm through its Series E venture round. MPM Capital led and was joined by fellow current backers Arch Venture Partners, Oxford Bioscience Partners, Omega Fund, and Physic Ventures. A representative from MPM will take a seat on the company's board. Concurrent with the financing, Elixir announced it had granted Novartis an option to buy the company for around $500mm.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
MPM leads $12mm Series E round for Elixir Pharmaceuticals
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice